Share Twitter LinkedIn Facebook Email Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.
Edetek’s CONFORM Platform: Streamlining Clinical Data Management in Oncology Trials General 3 Mins Read
High-Dose Chemotherapy for Recurrent Germ Cell Tumors: ASCO 2024 Study Results – Hedyeh Ebrahimi, MD – City of Hope ASCO Annual Meeting 2 Mins Read